Skip to main content

American Oncology Network Welcomes Robert J. McDonald, MD, FACNM, as Radiology Medical Director and In-House Reading Radiologist

Dr. McDonald’s Role Supports AON’s Growth in Radiotheranostics and Network-Wide RLT Capabilities

FORT MYERS, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) — American Oncology Network (AON), one of the nation’s fastest-growing community oncology networks, is pleased to announce the addition of Robert J. McDonald, MD, FACNM – a nationally recognized, board-certified nuclear medicine physician – as Radiology Medical Director and in-house reading radiologist. In this role, Dr. McDonald will support AON’s strategic expansion of radiotheranostic services throughout the network and strengthen AON’s commitment to delivering cutting-edge cancer care close to where patients live and work.

13719_AON_Robert-McDonald_Press-Release_Headshot_251204_V1 (3)Dr. McDonald will serve as the primary reading radiologist for AON partner practices Florida Oncology & Hematology (FOH) in Naples and Fort Myers, and Central Georgia Cancer Care (CGCC) in Macon, providing expert interpretations for PET and CT imaging. He will also perform advanced radiotheranostic therapies at the Naples and Fort Myers location, while overseeing radiology services as Medical Director at each practice he supports.

As AON continues to expand its radiotheranostic footprint, Dr. McDonald will play an integral role in developing physicians, supporting future program growth, and bringing advanced RLT treatment options to more AON practice sites in 2026. The Nuclear Regulatory Commission (NRC) requires new Authorized Users of radioligand therapies to complete clinical preceptorships, and part of Dr. McDonald’s position includes conducting these preceptorships on-site when needed, helping ensure safe, timely expansion of radioligand expertise across the network.

In addition, Dr. McDonald will lead clinical refinement of AON’s RLT protocols and assist in the adoption and rollout of newly FDA-approved radiotheranostic therapies – further positioning AON at the forefront of innovation in community oncology.

“AON is at the leading edge of radiotheranostics in community oncology, and Dr. McDonald’s expertise will accelerate our ability to bring groundbreaking radioligand treatments to more patients across the country,” said Todd Schonherz, AON chief executive officer. “His leadership in clinical training, protocol development, and program expansion will be essential as we scale radiotheranostic services to additional AON practice sites in 2026 and beyond. We are proud to welcome him and look forward to what his presence will make possible for our physicians, our practices, and the patients we serve.”

“Bringing Dr. McDonald into these roles allows us to enhance the quality, continuity, and cost-effectiveness of radiological services across our practices,” said Guy Messer, AON vice president of radiation and radiology services. “His expertise strengthens our ability to deliver timely imaging and treatment while also advancing the expansion of radiotheranostics within AON – a core element of our commitment to improving access to next-generation cancer care in community settings.”

Dr. McDonald joins AON with more than 30 years of experience in diagnostic imaging and radioligand therapies. He previously served as the Medical Director of Imaging Services for Florida Cancer Specialists & Research Institute, specializing in PET/CT interpretation and therapeutic nuclear medicine.

His career includes leadership appointments at MD Anderson Cancer Center Orlando, extensive work with Radiology Regional Center in Southwest Florida, and leadership positions in major medical centers in Oregon and California. He has also held multiple leadership roles within the Society of Nuclear Medicine & Molecular Imaging and is a Fellow of the American College of Nuclear Medicine.

Dr. McDonald is a respected researcher, educator, and speaker who has contributed to numerous clinical studies and national presentations advancing nuclear medicine. He earned his medical degree from the Medical College of Virginia and completed his nuclear medicine residency at the University of California Irvine Medical Center.

About American Oncology Network
American Oncology Network (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success and viability of community oncology and other specialties. Founded in 2018, AON’s rapidly expanding network represents more than 300 providers practicing across 20 states. AON pioneers innovative healthcare solutions through its physician-led model, fostering value-based care that improves patient outcomes while reducing costs and expanding access to quality care. AON equips its network physicians with the tools they need to thrive independently while providing comprehensive support, integrated revenue-diversifying ancillary services, and practice management expertise, enabling physicians to focus on what matters most – providing the highest standard of care for every patient. AON is committed to promoting health equity by addressing disparities in cancer care and ensuring that all patients have access to the care they need to achieve optimal health outcomes. With a focus on innovation and collaboration, AON is shaping the future of community oncology. For more information, please visit AONcology.com or follow us on LinkedInFacebookX (formerly Twitter) and YouTube.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f6a63acb-8ae5-4362-ac2b-f9af8d46ae1d

CONTACT: Contact:
Karen Riley Sawyer
American Oncology Network
Karen.Sawyer@AONcology.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.